Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
infection
Biotech
X4 scores a phase 3 win for immune deficiency disorder drug
Four months after laying off staff, X4 says its WHIM syndrome therapy improved white blood cell counts in patients during a phase 3 trial.
Annalee Armstrong
Nov 30, 2022 10:45am
Could a single pill outsmart a tumor's resistance mechanisms?
Mar 29, 2021 10:00am
Gilead snaps ups German virology biotech MYR
Dec 10, 2020 8:55am
Takeda's maribavir hits phase 3 goal
Dec 4, 2020 8:47am
Finch nets $90M to push C. diff microbiome med toward FDA filing
Sep 17, 2020 7:00am
Lumen hires Spigarelli to lead infectious disease work
Sep 10, 2020 8:35am